LT4331607T - Kieta farmacinė kompozicija, kurios sudėtyje yra 2-{4-[n-(5,6- difenilpirazin-2-il)-n-izopropilamino]butiloksi}-n-(metilsulfonil) acetamidas - Google Patents

Kieta farmacinė kompozicija, kurios sudėtyje yra 2-{4-[n-(5,6- difenilpirazin-2-il)-n-izopropilamino]butiloksi}-n-(metilsulfonil) acetamidas

Info

Publication number
LT4331607T
LT4331607T LTEP23214939.3T LT23214939T LT4331607T LT 4331607 T LT4331607 T LT 4331607T LT 23214939 T LT23214939 T LT 23214939T LT 4331607 T LT4331607 T LT 4331607T
Authority
LT
Lithuania
Prior art keywords
diphenylpyrazin
butyloxy
isopropylamino
methylsulfonyl
acetamide
Prior art date
Application number
LTEP23214939.3T
Other languages
English (en)
Inventor
Shouji Furuta
Hironori Mukai
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59014064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4331607(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of LT4331607T publication Critical patent/LT4331607T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP23214939.3T 2015-12-02 2016-12-01 Kieta farmacinė kompozicija, kurios sudėtyje yra 2-{4-[n-(5,6- difenilpirazin-2-il)-n-izopropilamino]butiloksi}-n-(metilsulfonil) acetamidas LT4331607T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015236034 2015-12-02

Publications (1)

Publication Number Publication Date
LT4331607T true LT4331607T (lt) 2025-06-10

Family

ID=59014064

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP23214939.3T LT4331607T (lt) 2015-12-02 2016-12-01 Kieta farmacinė kompozicija, kurios sudėtyje yra 2-{4-[n-(5,6- difenilpirazin-2-il)-n-izopropilamino]butiloksi}-n-(metilsulfonil) acetamidas

Country Status (32)

Country Link
US (2) US10821108B2 (lt)
EP (3) EP4331607B1 (lt)
JP (1) JP6825574B2 (lt)
KR (1) KR102759845B1 (lt)
CN (1) CN108289890B (lt)
AU (1) AU2016366073B2 (lt)
BR (1) BR112018009534B1 (lt)
CL (1) CL2018001464A1 (lt)
CO (1) CO2018006834A2 (lt)
DK (1) DK4331607T3 (lt)
EC (1) ECSP18049108A (lt)
ES (1) ES3030325T3 (lt)
FI (1) FI4331607T3 (lt)
HR (1) HRP20250572T1 (lt)
HU (1) HUE071411T2 (lt)
IL (2) IL310203A (lt)
LT (1) LT4331607T (lt)
MX (1) MX385595B (lt)
MY (1) MY198164A (lt)
PE (1) PE20181072A1 (lt)
PH (1) PH12018501161B1 (lt)
PL (1) PL4331607T3 (lt)
PT (1) PT4331607T (lt)
RS (1) RS66791B1 (lt)
RU (1) RU2735547C2 (lt)
SA (1) SA518391686B1 (lt)
SG (1) SG11201804320QA (lt)
SI (1) SI4331607T1 (lt)
TW (1) TWI750143B (lt)
UA (1) UA124002C2 (lt)
WO (1) WO2017098998A1 (lt)
ZA (1) ZA201804387B (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
CN111565720A (zh) * 2017-11-16 2020-08-21 日本新药株式会社 控释制剂
TW201936175A (zh) 2018-02-21 2019-09-16 日商日本新藥股份有限公司 粒狀組合物、粒狀組合物之製造方法、及粒狀組合物之溶出性改善方法
WO2020157730A1 (en) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite
US20210069187A1 (en) * 2019-05-11 2021-03-11 RK Pharma Solutions LLC Stable pharmaceutical composition of Selexipag
CN114555088A (zh) * 2019-10-23 2022-05-27 埃科特莱茵药品有限公司 包含赛乐西帕的药物组合物
WO2021106877A1 (ja) 2019-11-25 2021-06-03 エセックス古河マグネットワイヤジャパン株式会社 絶縁電線、コイル、及び電気・電子機器
TWI908789B (zh) * 2020-04-10 2025-12-21 日商日本新藥股份有限公司 固形製劑及其製造方法
CN112220770B (zh) * 2020-12-17 2021-04-09 上海翰森生物医药科技有限公司 司来帕格的药物组合物及其制备方法
WO2022240378A1 (en) * 2021-05-11 2022-11-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A stable pharmaceutical composition comprising selexipag

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3145431B2 (ja) 1991-08-20 2001-03-12 日本酸素株式会社 安定同位体標識蛋白質の製造法および試薬キット
JP3126683B2 (ja) 1996-04-16 2001-01-22 武田薬品工業株式会社 D−マンニトールおよびその製造法
US20010001106A1 (en) 1996-04-16 2001-05-10 Tomohiro Yoshinari D-mannitol and its preparation
EP1282416A2 (en) 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
ES2211738T3 (es) 2000-08-03 2004-07-16 Pfizer Products Inc. Derivados de diazabiciclooctano y sus usos terapeuticos.
TWI316055B (lt) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
EP1551401A4 (en) 2002-09-20 2006-03-22 Merck & Co Inc MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST
JP2004269513A (ja) 2003-02-19 2004-09-30 Rohto Pharmaceut Co Ltd 固形製剤
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
CA2687794C (en) 2007-05-28 2015-01-27 Jin Satomi Spherical particle of crystalline mannitol
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
TW200924768A (en) 2007-10-12 2009-06-16 Astrazeneca Ab Composition
ES2393640T3 (es) 2008-02-13 2012-12-26 Dainippon Sumitomo Pharma Co., Ltd. Comprimidos bucodisgregables
CN104761509A (zh) 2008-02-28 2015-07-08 日本新药株式会社 纤维化抑制剂
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
CN102065864B (zh) 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
HRP20151443T1 (hr) 2008-06-23 2016-01-29 Nippon Shinyaku Co., Ltd. Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
LT2447254T (lt) 2009-06-26 2018-01-10 Nippon Shinyaku Co., Ltd. Kristalai
EP2913047B1 (en) 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CN103690496B (zh) 2013-12-27 2015-04-01 哈药集团生物工程有限公司 一种含有奥扎格雷钠的冻干药物组合物

Also Published As

Publication number Publication date
EP4501404A3 (en) 2025-05-07
EP3384911A1 (en) 2018-10-10
CL2018001464A1 (es) 2018-10-19
EP4331607A3 (en) 2024-05-29
PH12018501161B1 (en) 2024-07-03
CN108289890A (zh) 2018-07-17
EP4331607B1 (en) 2025-04-30
CO2018006834A2 (es) 2018-07-10
AU2016366073B2 (en) 2021-08-26
SI4331607T1 (sl) 2025-06-30
ZA201804387B (en) 2020-12-23
JP6825574B2 (ja) 2021-02-03
ECSP18049108A (es) 2018-10-31
TWI750143B (zh) 2021-12-21
BR112018009534B1 (pt) 2023-11-07
EP3384911A4 (en) 2019-05-15
SG11201804320QA (en) 2018-06-28
SA518391686B1 (ar) 2024-03-03
US20180325895A1 (en) 2018-11-15
IL259461A (en) 2018-07-31
PH12018501161A1 (en) 2019-01-21
BR112018009534A2 (pt) 2018-11-06
JPWO2017098998A1 (ja) 2018-09-20
EP4501404A2 (en) 2025-02-05
MY198164A (en) 2023-08-08
MX2018006343A (es) 2018-08-01
IL310203A (en) 2024-03-01
KR102759845B1 (ko) 2025-01-23
CN108289890B (zh) 2021-04-27
US10821108B2 (en) 2020-11-03
PT4331607T (pt) 2025-05-22
AU2016366073A1 (en) 2018-06-14
EP4331607A2 (en) 2024-03-06
HRP20250572T1 (hr) 2025-07-04
RU2018123304A3 (lt) 2020-04-02
PL4331607T3 (pl) 2025-06-16
TW201720444A (zh) 2017-06-16
RU2735547C2 (ru) 2020-11-03
MX385595B (es) 2025-03-18
RS66791B1 (sr) 2025-06-30
US10828298B2 (en) 2020-11-10
HUE071411T2 (hu) 2025-08-28
PE20181072A1 (es) 2018-07-04
ES3030325T3 (en) 2025-06-27
FI4331607T3 (fi) 2025-06-03
DK4331607T3 (da) 2025-05-19
CA3005169A1 (en) 2017-06-15
US20180333413A1 (en) 2018-11-22
KR20180081141A (ko) 2018-07-13
WO2017098998A1 (ja) 2017-06-15
NZ742784A (en) 2024-08-30
RU2018123304A (ru) 2020-01-09
UA124002C2 (uk) 2021-07-07

Similar Documents

Publication Publication Date Title
ZA201804387B (en) Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
FI3328843T3 (fi) 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
SG11201706877RA (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
DK3362445T3 (da) Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed
IL254124A0 (en) New 3-indole-transformed histories, medicinal preparations and methods of use
PT3331864T (pt) Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
PT3580208T (pt) Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro
IL258160B (en) Biaryl derivatives, pharmaceutical preparations containing them and their uses
IL262929B1 (en) Preparations for treatment, methods of their preparation and their uses
EP3275452A4 (en) Pharmaceutical composition containing silibinin
IL243737B (en) History of -2amino-4-[3-(-7 fluoro-2-oxo-isoquinolin-1-yl)phenyl]-6-azoloamino-5,3,1-triazine and pharmaceutical preparations containing them
IL304109A (en) Pharmaceutical preparations containing spinamide
SG11201705543VA (en) Sulfonamide pharmaceutical composition
PT3632436T (pt) Composição farmacêutica compreendendo sais de lenvatinib
LT3259255T (lt) (2r,4r)-5-(5`-chlor-2`-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentano rūgštis
IL267708A (en) Oxalate salts of tianeptine and polymorphs thereof, preparations containing them and their uses
IL271513A (en) Innovative pharmaceutical composition
DK3290023T3 (da) Farmaceutisk sammensætning med langvarig frigivelse, som indeholder rivastigmin
SI3558261T1 (sl) Farmacevtski sestavki, ki obsegajo safinamid
PL3329939T3 (pl) Stała kompozycja farmaceutyczna nienadająca się do nadużywania
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof